<DOC>
	<DOC>NCT00694135</DOC>
	<brief_summary>The purpose of this study is to define a safe and effective dose of iontophoretic delivery of dexamethasone phosphate ophthalmic solution using the EyeGate® II Drug Delivery System in patients with non-infectious anterior segment uveitis.</brief_summary>
	<brief_title>Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis</brief_title>
	<detailed_description>This is a randomized, double-masked, parallel group, dose-comparison, exploratory study of four doses of iontophoretic delivery of dexamethasone phosphate ophthalmic solution in patients with non-infectious anterior segment uveitis. The current study will evaluate the safety, tolerability, and efficacy of this technology at the four dose levels to determine a safe effective dose appropriate for future trials.</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Uveitis, Anterior</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>• Noninfectious anterior uveitis Uveitis of infectious etiology Previous anterior uveitis episode ≤ 4 weeks prior to baseline Intraocular pressure (IOP) ≥ 25 mmHg at baseline, a history of glaucoma, and/or patients who require ocular antihypertensive medications Topical corticosteroid treatment in either eye &lt; 48 hours prior to baseline Oral corticosteroid or intraorbital corticosteroid treatment in either eye &lt; 2 weeks prior to baseline Active intermediate or posterior uveitis</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Iontophoresis</keyword>
	<keyword>Non-Infectious Acute Anterior Segment Uveitis</keyword>
	<keyword>Ophthalmology</keyword>
</DOC>